Skip to content

Innoviva, Inc. INVA Free cash flow yield

Free cash flow yield at other companies

Pfizer logo
PfizerPFE
7.8%+4.6pp
Merck & Co. logo
Merck & Co.MRK
4.7%-2.8pp
AbbVie logo
AbbVieABBV
5.2%+1.0pp
Insmed logo
InsmedINSM
-2.6%-0.9pp
Savara logo
SavaraSVRA
-9.6%-3.3pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
25.2%+23.0pp

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+30.7%
Enterprise value$1.41B-4.2%
P/E3.5×
P/S4.2×+0.5×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Innoviva, Inc.’s 10-Q, filed May 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s free cash flow yield?
Innoviva, Inc. (INVA) reported free cash flow yield of 17.6% in Q1 2025.
How has Innoviva, Inc.'s free cash flow yield changed year-over-year?
Innoviva, Inc.'s free cash flow yield increased by 11.5% year-over-year, from 15.8% to 17.6%.
What is the long-term trend for Innoviva, Inc.'s free cash flow yield?
Over 4 years (2020 to 2024), Innoviva, Inc.'s free cash flow yield has grown at a -16.9% compound annual growth rate (CAGR), from 36.4% to 17.3%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.